University of Minnesota - Carlson School of Management

SVP of Business Development and Strategy at Rubius Therapeutics

President and CEO of AIRNA, a company pioneering the discovery and development of RNA editing therapeutics. AIRNA emerged from stealth with a $30 million initial financing led by ARCH Venture Partners, and is headquartered in Cambridge, MA, with research operations in Tübingen, Germany.

AIRNA

President and Chief Executive Officer

Member of the Board of Advisors for Navega Therapeutics, a leading epigenetic gene regulation company founded by Prashant Mali and Ana Moreno.

Navega Therapeutics

Member of the Board of Advisors

Consulting for biopharma companies and venture capital firms on bringing transformative medicines to patients, corporate strategy and BD, and value creation, while actively pursuing new opportunities to build a great organization to fulfill a mission of transforming the lives of patients with severe disease.

Self employed

Consultant and Advisor

CEO and President of Diagon Therapeutics, a cellular regenerative medicines platform company seed funded by 5AM, Qiming, MRL (Merck), T1D Fund, and CCRM. Developed strategic vision, executed research plan, led seed extension fundraising, and managed winding down company and returning funds to investors after failing to generate key derisking data.

4:59 NewCo, a 5AM Ventures Company

Managed company-wide transformation to optimize employee engagement, operations, research, facilities, supply chain, and clinical for COVID environment, led strategic pivot toward oncology, and executed BD deals. Lead corporate strategy, search and evaluation, and business development functions.

Rubius Therapeutics

SVP of Business Development and Strategy

Negotiated and executed >$1b strategic partnership with AbbVie, negotiated terms for >$1b strategic partnership with Takeda, inlicensed multiple technologies, and received 2017 Fierce 15 award. Led business development, corporate strategy, and PR/IR functions.

Turnstone Biologics

SVP of Corporate Development

Raised Series B financing with Polaris, Nano Dimension, and Google Ventures, and negotiated and executed multiple Pharma and Biotech contracts. Responsible for corporate strategy, business development, strategic alliances, new discovery technologies and multiple operational functions.

SQZ Biotech

Chief Business Officer

Led the US commercial model development and pre-launch marketing plans and reimbursement strategies for Kymriah, a CD-19 CAR T cell therapy.

Novartis

Cell and Gene Therapies, US CAR T cell Marketing

Corporate Executive commercial rotation in sales, brand marketing, and payor managed markets. Ranked as #1 US Account Manager in sales performance. Completed leadership programs and Harvard Business School and Tuck Business School at Dartmouth College.

Gilenya Account Manager

Led strategy, market intelligence and RxGx functions for global company with $9 billion revenue and 25k employees, and served as Sandoz Executive Committee member.

Sandoz Global Head of Strategy and Market Intelligence; Sandoz Executive Committee Member

Chief of Staff for CEO of #2 generic pharma company.  Promoted to Executive Committee after eight months.

Sandoz Assistant to CEO

Managed project and client teams on strategic and operational health care engagements. Expertise in acquisition and merger due diligence and integration, pharma and device sales and marketing optimization, and US health care insurance strategies.

McKinsey & Company

Engagement Manager

1-year leave of absence from McKinsey to travel with my wife through New Zealand, Australia, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, China, Nepal and India.  Wrote 318 page (105,000 word) novel (yet to be published).

Writer

Associate

Sales advisor acquiring and managing private client wealth, responsible for managing over $40 million in client assets (average client size greater than $1 million). Received Executive Club award, ranked #2 (out of 100) amongst reps with less than three years experience.

Kris Elverum